Back to search results

Study of Tradipitant for Nausea and Vomiting from GLP-1R Agonists

This study is looking at whether an oral capsule called Tradipitant can help reduce nausea and vomiting caused by GLP-1R agonist medications. These medications are often used for weight management. You might be able to join if you are between 18 and 65 years old, have a Body Mass Index (BMI) between 25 and 40 kg/m², and do not have serious medical problems like diabetes. The study will compare Tradipitant to a placebo (an inactive capsule) to see if participants taking Tradipitant have fewer vomiting episodes per week. The study aims to enroll 280 participants, but its current recruitment status is unclear.

Study design
This study is interventional and placebo-controlled, meaning some participants will receive Tradipitant and others will receive a placebo. It involves two treatment groups and plans to enroll 280 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, vomiting episodes, will be measured at 1 week.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07446439

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Recruiting
PHASE3Ages 18–65InterventionalTreatment
Vanda Pharmaceuticals
~280 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:TradipitantPlacebo

At a glance

Recruiting sites
3 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.
Measured over 1 week

Conditions

Nausea and Vomiting
Obesity

Explore related trials

NauseaObesityOverweightVomiting

Where it's being run

10 sites across 6 states
California3
New York2
Texas2
Florida1
New Jersey1
Virginia1

Study leadership

  • Vanda Pharmaceuticals Inc. · STUDY_DIRECTOR · Vanda Pharmaceuticals Inc.

Who to contact

Vanda Pharmaceuticals
[email protected]
(202) 734-3400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body Mass Index ≥ 25 and \< 40 kg/m\^2
No serious medical problems or chronic diseases, specifically no type I or type II diabetes

Exclusion

Another disorder that contributes to gastrointestinal symptoms
History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
Exposure to any investigational medication within the past 60 days

What this trial measures

  • Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.1 week

    A questionnaire called the Nausea Vomiting Daily Diary (NV-DD) will be completed once a day, which will be used to collect data for this endpoint. The NV-DD asks participants to record their vomiting frequency in a 24-hour period.